Posted by Michael Wonder on 12 Apr 2018
Ohara cuts price of generic drug for leukaemia
11 April 2018 - Ohara Pharmaceutical Co. has reduced the price of its generic drug for leukaemia to about half the price of the generic drugs sold by its competitors to encourage leukaemia patients to use more affordable medication.
The drug is prescribed mainly to those who are suffering from chronic myelocytic leukemia.
The original medicine, Glivec, which was put on the market in 2001, is known for its effectiveness against the disease, as its users have a five-year survival rate of more than 90%.
